PharVision Advisers’s Nomura Holdings NMR Stock Holding History

PharVision Advisers’s Portfolio NMR Stock Details NMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-32,948	Closed	-$276K	–	464
2025 Q4	$276K	Buy	+32,948	New	+$246K	0.14%	326

Other funds holding NMR

DSC

Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PharVision Advisers's NMR Position: Q1 2026 in Review

PharVision Advisers sold out of Nomura Holdings (NMR) in Q1 2026, closing a stake of 32,948 shares — an estimated $276K sold.

PharVision Advisers first reported a position in NMR in Q4 2025 and held it in 1 quarter. The position peaked at $276K in Q4 2025. 271 funds tracked by Wall St. Rank hold NMR as of Q1 2026.

PharVision Advisers reported no remaining Nomura Holdings position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 32,948 Nomura Holdings shares in Q1 2026, an estimated $276K.
PharVision Advisers first reported a position in Nomura Holdings in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Nomura Holdings position peaked at $276K in Q4 2025.
271 funds tracked by Wall St. Rank held Nomura Holdings as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.